AN2 Therapeutics, Inc. (ANTX)

Market Cap	296.47M
Revenue (ttm)	n/a
Net Income (ttm)	-36.66M
Shares Out	19.40M
EPS (ttm)	-12.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,715
Open	15.47
Previous Close	15.47
Day's Range	14.38 - 15.89
52-Week Range	6.88 - 23.58
Beta	n/a
Analysts	Buy
Price Target	23.80 (+55.76%)
Earnings Date	Feb 8, 2023

About ANTX

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2022
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: ANTX

Analyst Forecast

According to 10 analysts, the average rating for ANTX stock is "Buy." The 12-month stock price forecast is $23.8, which is an increase of 55.76% from the latest price.

Price Target

$23.8

(55.76% upside)

Analyst Consensus: Buy